Skip to main content
Top
Published in: Abdominal Radiology 5/2021

01-05-2021 | Pancreas

Feasibility of wide detector CT perfusion imaging performed during routine staging and restaging of pancreatic ductal adenocarcinoma

Authors: Ryan B. O’Malley, Erik V. Soloff, Andrew L. Coveler, Danielle H. Cox, Nitin Desai, Janet M. Busey, Greta M. Valentin, Carolyn L. Wang

Published in: Abdominal Radiology | Issue 5/2021

Login to get access

Abstract

Purpose

To evaluate the feasibility of CT perfusion performed during routine multiphase contrast-enhanced CT on a 160 mm wide-coverage 256-slice scanner in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods

Fifty-seven patients had a CT perfusion acquisition during their routine multiphase CT. Perfusion was performed 5 to 42.5 s (15 passes at 2.5 s intervals) after intravenous contrast administration (4.2–5 ml/s), followed by pancreatic parenchymal and portal venous phases for clinical interpretation. Perfusion maps were generated and blood flow (BF), blood volume (BV), and permeability surface area product (PS) for tumor and uninvolved pancreas were calculated using deconvolution algorithms and compared to existing similar publications. Radiation dose information was recorded and size-specific dose estimate (SSDE) was calculated using body dimensions.

Results

Diagnostic quality of standard images was unaffected by performing the perfusion acquisition. Average tumor center BF was 20.8 ± 12.1 ml/100 g/min, BV 2.5 ± 2.1 ml/100 g and PS 15.5 ± 39.4 ml/100 g/min. Average pancreas BF was 90.8 ± 50.2 ml/100 g/min, BV 11.9 ± 4.3 ml/100 g and PS 33.6 ± 27.7 ml/100 g/min. For the perfusion acquisition, mean SSDE was 57 ± 11 mGy, CTDIvol 43 ± 6 mGy and DLP 685 ± 100 mGy-cm.

Conclusion

Adding a perfusion CT acquisition to standard pancreatic CT protocol is feasible using a wide-detector 256-slice CT scanner and adds quantitative information while maintaining diagnostic quality of the standard of care examination. This novel protocol adds no time or cost to the examination and yields perfusion parameters that are comparable to existing literature using a separate dedicated perfusion protocol.

Graphic abstract

Literature
1.
go back to reference Nelson DW, Chang S-C, Grunkemeier G, et al (2018) Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery. Ann Surg Oncol 25:4012–4019.CrossRef Nelson DW, Chang S-C, Grunkemeier G, et al (2018) Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery. Ann Surg Oncol 25:4012–4019.CrossRef
2.
go back to reference Zhong J, Switchenko J, Behera M, et al (2018) Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg Oncol 25:1026–1033.CrossRef Zhong J, Switchenko J, Behera M, et al (2018) Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg Oncol 25:1026–1033.CrossRef
4.
go back to reference Luberice K, Downs D, Sadowitz B, et al (2017) Has survival improved following resection for pancreatic adenocarcinoma? Am J Surg 214:341–346.CrossRef Luberice K, Downs D, Sadowitz B, et al (2017) Has survival improved following resection for pancreatic adenocarcinoma? Am J Surg 214:341–346.CrossRef
5.
go back to reference Cassinotto C, Mouries A, Lafourcade J-P, et al (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 273:108–116.CrossRef Cassinotto C, Mouries A, Lafourcade J-P, et al (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 273:108–116.CrossRef
6.
go back to reference Ferrone CR, Marchegiani G, Hong TS, et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17.CrossRef Ferrone CR, Marchegiani G, Hong TS, et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17.CrossRef
7.
go back to reference Katz MHG, Fleming JB, Bhosale P, et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749–5756.CrossRef Katz MHG, Fleming JB, Bhosale P, et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749–5756.CrossRef
8.
go back to reference Klotz E, Haberland U, Glatting G, et al (2015) Technical prerequisites and imaging protocols for CT perfusion imaging in oncology. Eur J Radiol 84:2359-2367.CrossRef Klotz E, Haberland U, Glatting G, et al (2015) Technical prerequisites and imaging protocols for CT perfusion imaging in oncology. Eur J Radiol 84:2359-2367.CrossRef
9.
go back to reference Prezzi D, Khan A, Goh V (2015) Perfusion CT imaging of treatment response in oncology. Eur J Radiol 84:2380–2385.CrossRef Prezzi D, Khan A, Goh V (2015) Perfusion CT imaging of treatment response in oncology. Eur J Radiol 84:2380–2385.CrossRef
10.
go back to reference Fukukura Y, Takumi K, Higashi M, et al (2014) Contrast-enhanced CT and diffusion-weighted MR imaging: Performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma. Eur J Radiol 83:612–619.CrossRef Fukukura Y, Takumi K, Higashi M, et al (2014) Contrast-enhanced CT and diffusion-weighted MR imaging: Performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma. Eur J Radiol 83:612–619.CrossRef
11.
go back to reference D’Onofrio M, Gallotti A, Mantovani W, et al (2013) Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. Eur J Radiol 82:227–233.CrossRef D’Onofrio M, Gallotti A, Mantovani W, et al (2013) Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. Eur J Radiol 82:227–233.CrossRef
12.
go back to reference Hamdy A, Ichikawa Y, Toyomasu Y, et al (2019) Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Radiology 292:628-635.CrossRef Hamdy A, Ichikawa Y, Toyomasu Y, et al (2019) Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Radiology 292:628-635.CrossRef
13.
go back to reference Aslan S, Nural MS, Camlidag I, et al (2019) Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions. Abdom Radiol 44:593–603.CrossRef Aslan S, Nural MS, Camlidag I, et al (2019) Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions. Abdom Radiol 44:593–603.CrossRef
16.
go back to reference Delrue L, Blanckaert P, Mertens D, et al (2011) Assessment of Tumor Vascularization in Pancreatic Adenocarcinoma Using 128-Slice Perfusion Computed Tomography Imaging. J Comput Assist Tomogr 35:434–438.CrossRef Delrue L, Blanckaert P, Mertens D, et al (2011) Assessment of Tumor Vascularization in Pancreatic Adenocarcinoma Using 128-Slice Perfusion Computed Tomography Imaging. J Comput Assist Tomogr 35:434–438.CrossRef
17.
go back to reference Xu J, Liang Z, Hao S, et al (2009) Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging 34:759–766.CrossRef Xu J, Liang Z, Hao S, et al (2009) Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging 34:759–766.CrossRef
18.
go back to reference Yadav AK, Sharma R, Kandasamy D, et al (2016) Perfusion CT – Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum? Pancreatology 16:979–987.CrossRef Yadav AK, Sharma R, Kandasamy D, et al (2016) Perfusion CT – Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum? Pancreatology 16:979–987.CrossRef
19.
go back to reference Schneeweiß S, Horger M, Grözinger A, et al (2016) CT-perfusion measurements in pancreatic carcinoma with different kinetic models: Is there a chance for tumour grading based on functional parameters? Cancer Imaging 16:43.CrossRef Schneeweiß S, Horger M, Grözinger A, et al (2016) CT-perfusion measurements in pancreatic carcinoma with different kinetic models: Is there a chance for tumour grading based on functional parameters? Cancer Imaging 16:43.CrossRef
20.
go back to reference Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76:S36–S42.CrossRef Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76:S36–S42.CrossRef
21.
go back to reference Kaufmann S, Schulze M, Horger T, et al (2015) Reproducibility of VPCT Parameters in the Normal Pancreas. Acad Radiol 22:1099–1105.CrossRef Kaufmann S, Schulze M, Horger T, et al (2015) Reproducibility of VPCT Parameters in the Normal Pancreas. Acad Radiol 22:1099–1105.CrossRef
Metadata
Title
Feasibility of wide detector CT perfusion imaging performed during routine staging and restaging of pancreatic ductal adenocarcinoma
Authors
Ryan B. O’Malley
Erik V. Soloff
Andrew L. Coveler
Danielle H. Cox
Nitin Desai
Janet M. Busey
Greta M. Valentin
Carolyn L. Wang
Publication date
01-05-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02786-y

Other articles of this Issue 5/2021

Abdominal Radiology 5/2021 Go to the issue

Classics in Abdominal Radiology

The beak sign of foramen of Winslow hernia

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.